Evidence map›Paper›PMID 39945414›Full record

ArticleJournal of psychopharmacology (Oxford, England)2025

The mechanism of action of clozapine.

Paul D Morrison, Sameer Jauhar, Allan H Young

Abstract read
In one paragraph

Article in Journal of psychopharmacology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Treatment of Parkinson's Disease-Related Psychosis.Clinical pharmacology : advances and applications · 2026
    Review
  10. Article
  11. Review
  12. The pharmacology underlying the unique antipsychotic efficacy of clozapine.Journal of psychopharmacology (Oxford, England) · 2025
    Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Paul D MorrisonNHS Highland Health and Social Care Partnership, Lochgilphead, Scotland.ORCID 0009-0006-8805-766X
Sameer JauharInstitute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK.ORCID 0000-0002-3878-3659
Allan H YoungInstitute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK.

Funding

Wellcome Trust
6 · The paper itself

Abstract

Previous hypotheses for the superiority of clozapine over other antipsychotics have failed to stand the test of time. Here we describe how the unique pharmacology of clozapine in the peripheral nervous system held clues for solving the puzzle of clozapine in the central nervous system. Clozapine appears to have been the prototype for a new class of antipsychotics, now entering clinical psychiatry, which activates muscarinic acetylcholine receptors.

Indexed as

Antipsychotic AgentsClozapineAnimalsCentral Nervous SystemHumansReceptors, MuscarinicAntipsychotic AgentsClozapineReceptors, MuscarinicacetylcholineagonistcholinergicclozapineCobenfyemraclidineKarXTM1M4mechanismmuscarinicpsychosisreceptorSchizophreniastriatumxanomeline

Identifiers

PMID39945414
PMCPMC11967075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.